Topical therapy with beta-antagonists, such as timolol, may cause unrecognized impairment of respiratory and cardiovascular function in elderly people. Beta-antagonists with intrinsic sympathomimetic or cardioselective properties, such as carteolol or betaxolol, may cause less impairment. In a randomized, double-masked study of glaucoma patients, over 60 years of age, without history of bronchospasm and who were using timolol (0.5%), 60 patients were allocated to betaxolol (0.5%) or carteolol (2%) or continued timolol (0.5%) treatment. Spirometry, pulse and blood pressure were measured on enrolment and after 4 weeks.
Introduction
Chronic open-angle glaucoma is asymptomatic until visual field is lost. Increasingly common with age, it affects about 5% of those over 65 years of age and is responsible for 15% of registrations for blindness in this age group [1] . The cause of chronic open-angle glaucoma is not fully understood but typically intraocular pressure (IOP) is high. Treatment is to lower IOP and topical therapy with beta-antagonists is the method most often employed. The non-selective betaantagonist timolol is the most commonly prescribed drug, being an excellent ocular hypotensive agent with few local side-effects [2] .
Eye-drops may be absorbed into the blood stream through the lacrimal sac and nasal mucosa, thus avoiding first-pass metabolism in the liver. Two drops of timolol 0.5% to both eyes can be equivalent to the 10 mg oral dose used to treat hypertension or angina [3] .
Topical timolol therapy impairs lung function tests of patients with asthma [4] or chronic obstructive airways disease [5] but has been thought safe in patients without history of bronchospasm. Elderly people have a high incidence of obstructive airways disease [6, 7] and recent studies suggest that unsuspected respiratory impairment is common among those with topical timolol [8, 9] . Topical beta-antagonists may also worsen heart failure, cause bradycardia and hypotension and are associated with an increased incidence of falls [10] [11] [12] .
Alternative drugs to timolol include the non-selective beta-antagonist carteolol, which is as effective an ocular hypotensive drug as timolol [13] . Carteolol has moderate partial agonist activity to both beta-1 and beta-2 adrenoceptors [14] . Thus when it occupies receptors, besides inhibiting effects of sympathetic activity or beta-stimulants, it has some stimulant activity of its own. This may modify the actions on effector organs such as the heart, bronchial and cardiovascular smooth muscle. For example, carteolol's intrinsic sympathomimetic activity (ISA) may produce superior ocular nerve perfusion relative to other beta-antagonists [15] , which may theoretically better preserve visual fields. The ISA of carteolol may also result in fewer respiratory and cardiovascular side-effects than timolol. There is evidence of less bradycardia and hypotension with topical carteolol than timolol [16, 17] as well as some suggestion that it results in less respiratory impairment [18, 19] . The relatively cardioselective beta-antagonist betaxolol [20] is another alternative. In those with airways obstruction [21] and elderly asymptomatic patients, it is associated with less respiratory impairment than timolol [9] . However, as with other selective beta-antagonists, betaxolol can cause bronchospasm and should not be given to people with reversible airways disease.
Most studies of systemic side-effects of topical betaantagonists given for glaucoma have not concentrated on elderly people, who are the greatest number with glaucoma. The present comparative, controlled study aimed to investigate changes in spirometry, IOP, resting pulse and blood pressure in elderly patients with no history of airways disease, when timolol is replaced by carteolol or betaxolol.
Methods
The study was approved by the local ethical committee. Sixty ambulant patients aged over 60 years with stable IOP using topical 0.5% timolol solution to both eyes were recruited from ophthalmology clinics. Patients had no history of airflow tract obstruction, had a mental test score [22] of more than seven out of ten and were able to self-administer eye-drops. They were not receiving oral beta-blocker or bronchodilator therapy and there was no history of recent (within 4 weeks) respiratory tract infection or heart failure. Based upon data from a previous study of spirometric changes when timolol was changed to betaxolol [9] , the study was designed to have 80% power to detect a change in mean FEV t of 0.15 1 with a significance level of 5%.
After obtaining informed consent, the patients' height, age and sex were noted as well as the time since they last put in their eye-drops. After 5 min resting in a chair, pulse (radial beats palpated in 1 min) and blood pressure (Korotkoff phase V [23] ) were recorded. IOP was then measured by Goldman aplanation tonometry. Spirometry {peak flow (PF), forced expiratory volume in one second (FEV!) and forced vital capacity (FVC)} was then done using a Micro Plus spirometer (Micro Medical Ltd., Rochester, Kent, UK [24] ). The values recorded were the best of three attempts.
On enrolment into the study we inquired, using standardized questions, as to the presence of: cough; wheeze; exertional and nocturnal dyspnoea. A dyspnoea score ranging 0, normal, to 4, dyspnoeic on slightest exertion [25] , was also recorded as well as the presence of local side-effects. Using randomized double-masked methodology, the pharmacy department allocated patients to change to carteolol 2% b.d. or betaxolol 0.5% b.d. to both eyes and a control group continuing timolol was recruited. After 28 days the outcome measures and symptom inquiry were repeated and the patients were asked if their breathing was 'better, worse or the same'. The numbers demonstrating a greater than 15% (-9,31)
•p = 0.048 for changes between timolol and betaxolol.
improvement in PF and FEVj [26] in spirometry were noted.
Patients were reviewed at approximately (i.e. within 2^h) the same time of day as their enrolment. The number of hours which had elapsed since they last instilled their drops was documented.
Results
Of 30 patients (17 women The carteolol and timolol groups showed no significant changes in mean PF or FEV] between enrolment and review. In the betaxolol group there was a significant increase in mean PF and FEV] and the differences in the changes between timolol and betaxolol and carteolol and betaxolol groups were statistically significant (p < 0.05 Mann-Whitney) [ Tables I and  II] . There was a small, but not statistically significant, improvement in mean FEV]/FVC ratio in the betaxolol group but no improvement in timolol or carteolol groups [ Table III ]. Three of those given betaxolol, but none of those carteolol or timolol, showed clinically significant change (greater than 15%) in spirometry.
On enrolment four of the patients included in the study had a resting pulse of less than 60 beats/min (two had pulse rates of 52 and two of 56 beats/min). There was no increase in mean heart rate in the groups changing to carteolol or continuing timolol and no patient increased their pulse by 20 beats/min or more. Two patients in the betaxolol group increased resting pulse rate by 20 beats/min when reviewed and there was an increase in mean resting pulse rate. The differences in the changes between timolol and betaxolol and carteolol and betaxolol groups were statistically significant (p < 0.05 Mann-Whitney) [ Table IV ].
There was no statistically significant change in mean values for systolic or diastolic blood pressures [ Table V] . No patient was hypotensive and none recorded a change in either systolic pressure of more than 20 mmHg or diastolic of more than 10 mmHg during the study.
There were significant falls in mean IOP in the timolol [-l.OmmHg, 95%CI (-0.1, -1.9)] and carteolol [-1.9 mmHg, 95% CI (-0.9, -2.9)] groups and a rise in the betaxolol [1.5 mmHg, 95% CI (2.7, 0.1)] group. The differences in the changes between timolol and betaxolol and carteolol and betaxolol groups were statistically significant (p < 0.05 Mann-Whitney) but not between carteolol and timolol groups [ Table VI] . No patient was judged to require additional therapy as a result of changing to betaxolol or carteolol.
Most patients noticed no subjective change in their breathing. In the group allocated to betaxolol, there was a slight fall in the number of patients admitting to 
Discussion
The absence of improvement in spirometry, either within the carteolol group or in comparison to the timolol group, suggests ISA of carteolol confers no advantage in respiratory function to elderly people over other non-selective beta-antagonists and should not be considered in those with respiratory disease. The study confirmed that changing to relatively cardioselective topical beta-antagonist therapy is associated with improvement in mean spirometry and revealed unsuspected reversible airflow tract obstruction in three (21%) of 14 patients.
Elderly patients are at risk of respiratory impairment when given beta-antagonists. However, other diseases may prevent respiratory symptoms becoming apparent. In addition, elderly people have less awareness of the changes in spirometry and may not notice a fall of 20% in FEV] [27] . This may explain why our study found little improvement in respiratory symptomatology even in the group which showed improved lung function.
Several patients were bradycardic when receiving • p < 0.001 for changes between timolol and betaxolol.
•p < 0.001 for changes between timolol and betaxolol. timolol, which may contribute to the reduced exercise tolerance found with topical timolol [9] as well as the development of heart failure. Glaucoma treatment with non-meiotic eye-drops is associated with an independent fivefold increase in risk of falling in elderly people [12] and impaired cardiovascular responses associated with topical beta-antagonist therapy may be part of the explanation for this increased risk. That changing to carteolol was not associated with an increase in mean resting pulse implies that the ISA of carteolol does not produce less bradycardia than timolol. Surprisingly, mean resting pulse rate increased significantly in the betaxolol group. This may be because plasma levels following topical administration of one drop to each eye of a betaxolol 0.5% solution are lower than with an equivalent therapeutic dose of 0.5% timolol [28] . In addition betaxolol is more lipophilic and protein-bound than timolol [29] and has a lower beta-1 receptor occupancy than timolol [30] at the doses we used. There were no significant changes in mean blood pressure in any group, though several patients recorded differences of lOmmHg between enrolment and review. When given with other anti-hypertensive medication topical therapy may, perhaps, precipitate hypotension. Betaxolol would seem to offer some cardiorespiratory advantages over timolol or carteolol.
Betaxolol was a less effective ocular hypotensive agent. There was a statistically significant rise in mean IOP compared with significant falls in the carteolol and timolol groups. The fall in the latter may be due to improved compliance. Though no patient recorded a pressure above 21 mmHg (the upper limit of normal), IOP reduction is regarded as the cornerstone in the management of glaucoma. Many patients require more than one topical medication to control IOP and the use of betaxolol rather than timolol or carteolol would increase the proportion of patients requiring several drugs. In addition, betaxolol is associated with more local side-effects which are likely to reduce patient compliance.
In summary, the ISA of carteolol confers no advantage in older patients' spirometry, pulse or blood pressure over timolol but it is well tolerated and is an excellent ocular hypotensive drug. In a group of elderly patients, without history of respiratory disease, changing to relatively cardioselective betaxolol therapy is associated with improved spirometry, a small improvement in respiratory symptoms and resting pulse rate. Elderly patients are especially vulnerable to the respiratory and cardiovascular side-effects of topical beta-antagonist therapy. We recommend routine measurement of pulse, blood pressure and spirometry • Four patients felt the stinging was so severe that they were reluctant to continue betaxolol. be performed in ophthalmology clinics on elderly patients receiving beta-antagonists. The identification of bradycardia, hypotension or a fall in PF and FEVj of more than 15% should prompt a review of alternatives to topical beta-antagonists.
